The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa

Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.

Abstract

Objective: Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target.

Methods: Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program.

Results: The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment.

Discussion: The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.

Keywords: anorexia nervosa; aripiprazole; dopamine; eating disorder; medication; receptor; treatment; weight gain.

MeSH terms

  • Adolescent
  • Anorexia Nervosa / drug therapy*
  • Aripiprazole / pharmacology
  • Aripiprazole / therapeutic use*
  • Body Mass Index
  • Dopamine Agonists / pharmacology
  • Dopamine Agonists / therapeutic use*
  • Female
  • Humans
  • Receptors, Dopamine D2 / agonists*
  • Retrospective Studies
  • Reward
  • Treatment Outcome
  • Weight Gain / drug effects*

Substances

  • Dopamine Agonists
  • Receptors, Dopamine D2
  • Aripiprazole